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ABSTRACT
Neuroblastoma (NB) is a pediatric tumor presenting at diagnosis either as 
localized or metastatic disease, which mainly involves the bone marrow (BM).The 
physical occupancy of BM space by metastatic NB cells has been held responsible for 
impairment of BM function. Here, we investigated whether localized or metastatic 
NB may alter hematopoietic lineages’ maturation and release of mature cells in the 
periphery, through gene expression profiling, analysis of BM smears, cell blood count 
and flow cytometry analysis.
Gene ontology and disease-associated analysis of the genes significantly under-
expressed in BM resident cells from children with localized and metastatic NB, as 
compared to healthy children, indicated anemia, blood group antigens, and heme 
and porphyrin biosynthesis as major functional annotation clusters. Accordingly, in 
children with NB there was a selective impairment of erythrocyte maturation at the 
ortho-chromic stage that resulted in reduced erythrocyte count in the periphery, 
regardless of the presence of metastatic cells in the BM. By considering all NB patients, 
low erythrocyte count at diagnosis associated with worse survival. Moreover, in the 
subset of metastatic patients, low erythrocyte count, hemoglobin and hematocrit 
and high red cell distribution width at follow-up also associated with worse outcome.
These observations provide an alternative model to the tenet that infiltrating 
cells inhibit BM functions due to physical occupancy of space and may open a 
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new area of research in NB to understand the mechanism(s) responsible for such 
selective impairment.
INTRODUCTION
Neuroblastoma (NB) is a pediatric tumor, whose 
biology and clinical behavior continuously puzzles 
researchers and clinicians. NB displays a broad 
spectrum of clinical features that vary from tumors that 
spontaneously regress [1] to metastatic disease at onset 
[2]. A genetic alteration, namely MYCN amplification, 
was demonstrated to control NB aggressiveness [3–5]. 
However, the number of driving mutations, essential 
to initiate and/or sustain tumor growth, has been 
identified only in a fraction of NB [6, 7]. NB was the 
first solid tumor found to selectively express a surface 
tumor-specific antigen, the GD2 di-sialoganglioside 
[8, 9], allowing a “precision medicine approach” for 
specific immunotherapy  [10], now included in standard 
therapeutic regimen for metastatic NB patients [2, 11]. 
Notwithstanding, the survival rate of NB patients treated 
with anti-GD2 antibodies increased only slightly [2].
The deep knowledge of NB tumor genetics and 
biology have allowed to establish effective treatments 
for some of NB patients, such as infants and children 
with localized, MYCN not amplified tumors, with 5-year 
survival rates between 90 and 100%, depending on age 
and stage [12]. Unfortunately, prognosis of children with 
either localized MYCN amplified tumors and of children 
with metastatic disease (high-risk patients) is still poor 
with 5-year survival rates around 65 and 30%, respectively 
[11, 13, 14]. High-risk NB patients that do not respond 
to standard chemotherapy or relapse have less than 10% 
5-year survival rate [15, 16].
Metastatic patients present massive bone marrow 
(BM) infiltration by NB cells that were considered 
identical to the primary tumor cells. However, in the last 
decade, it has become evident that metastatic cells were 
not exactly the same as the correspondent primary tumor 
cells [17, 18]. In addition, many studies demonstrated that 
the properties of both neoplastic and resident cells were 
deeply modified by the bi-directional signals occurring 
within the local microenvironment [19].
Based on these premises, we previously studied the 
gene expression profiles of BM-infiltrating NB cells as 
compared to NB primary tumor cells [20]. BM-infiltrating 
NB cells shared the same neuronal characteristics of 
primary tumor cells, but acquired expression of surface 
proteins typical of the hematopoietic cell lineages. BM-
infiltrating NB cells showed also different microRNA 
profile [21], and different rates of potential driving 
mutations and chromosomal rearrangements [22, 23]. 
Altogether, these data suggested that the BM environment 
could modify NB cell features.
As for the resident BM cells, we previously showed 
that in NB patients their gene expression profile was 
different from that of healthy children, regardless of the 
presence of BM-infiltrating NB cells. These data suggested 
a remote effect operated by the primary tumor cells on 
the BM resident cells [24]. In particular, the genes over-
expressed in NB patients belonged to the IFN and IFRD 
signatures, suggestive of innate immunity activation, 
whereas the most under-expressed gene was CXCL12 
(SDF-1) [24].
To better characterize the BM microenvironment 
of NB patients, we here investigated whether the genes 
under-expressed in BM resident cells belonged to 
particular functional pathway(s) and/or signature(s) which 
may relate to impairment of BM function.
RESULTS
Gene expression profiles of BM resident cells 
from NB patients and healthy children
The gene expression profile of BM resident cells 
from 44 NB patients, whose main features are shown in 
Table 1, were compared to those of BM resident cells 
from 13 healthy children (http://www.ncbi.nlm.nih.gov/
geo/, GEO accession number GSE90689). By setting the 
statistical significance for differential expression at 0.01 
Bonferroni’s adjusted P value, samples from patients 
with metastatic and localized NB showed to under-
express 641 and 1239 genes, respectively (Supplementary 
Table 1A and 1B), as compared to BM resident cells 
from healthy children. Twenty-nine genes were found 
to be differentially expressed between metastatic and 
localized NB, but statistical significance was not reached 
(Supplementary Table 1C), confirming that the gene 
expression profiles of BM resident cells from metastatic 
and localized NB patients were similar [24]. Thus, by 
considering all NB patients in our cohort, the genes 
significantly under-expressed were 1085, of whom 533 
in common between metastatic and localized patients 
(Supplementary Table 1D and 1E, respectively).
Gene ontology analysis
To check whether the under-expressed genes 
clustered for annotation or associated to a specific disease, 
the list of 533 genes under-expressed in both metastatic 
and localized NB (Supplementary Table 1E) was run 
into the DAVID bioinformatics database. In addition 
to functional annotation clusters containing more than 
one-hundred genes, such as phosphoprotein, acetylation, 
cytosol and cytoplasm, the most significant functional 
annotation clusters referred to genes involved in anemia, 
blood group antigens, heme and porphyrin biosynthesis 
(Table 2). Moreover, 63 of the 533 under-expressed genes 
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associated to diseases involving erythrocytes (Table 3). 
Altogether these data suggested possible alterations of 
erythropoiesis in NB patients.
Since a cluster of 16 genes belonged to blood group 
antigens expressed on mature erythrocytes, we checked in 
a cohort of 115 NB patients (Table 1, CBC) whether the 
distribution into the ABO system and the frequency of Rh 
D antigen was in accordance with that of the European 
population [25, 26]. As shown in Supplementary Figure 1, 
no difference was observed, thus excluding any type of 
skewing for NB susceptibility depending on blood group 
antigens.
Erythrocyte precursors and erythroblasts are 
altered in BM samples from NB patients
Since the expression profiles of BM resident cells 
from NB patients suggested a possible alteration in 
erythrocyte count, we next scored BM smears from 70 
NB patients with localized (L, N=20) or metastatic (M, 
N=50) NB (Table 1, Smears) for total myeloid-, erythroid- 
and lymphoid-precursors, and compared them to BM 
smears from 11 healthy children. As shown in Figure 1A, 
healthy children showed higher proportions of erythrocyte 
precursors (median±SEM % of total cells: 26±2.48) than 
patients with localized (23±1.75, p=0.02) or metastatic 
(21±1.68, p=0.03) NB. Conversely, no difference was 
detected in count of myeloid (healthy: 56±2.3; L NB: 
58±2.9; M NB: 55±2.5) and lymphoid (healthy: 12±2; L 
NB: 16±2.7; M NB: 15±1.6) precursors.
The same BM smears were then scored for presence 
of erythroid precursors. No significant difference was 
detected in the percentage of pro-erythroblasts (mean±SD 
% of total cells: healthy: 4.1±2.2; L NB: 4.5±1.8; M NB: 
4.6±2.5), baso-erythroblasts (healthy: 14.2±8.6; L NB: 
17.7±8.8; M NB: 15.4±9.7) and poly-chromatophilic 
erythroblasts (healthy: 38.2±8.4; L NB: 39.5±8.8; M 
NB: 41.4±10), whereas the percentage of ortho-chromic 
erythroblasts was significantly higher in healthy children 
(43.2±5.8) than in patients with localized (38.6±10.1, 
p=0.01) and metastatic (36.9±11.7, p=0.04) NB 
(Figure 1B).
Maturation of erythrocytes is altered in BM 
from NB patients
To confirm the data obtained in BM smears 
suggestive of a selective impairment of late stage 
erythrocyte maturation, we collected BM aspirates 
from 16 NB patients (Table 1, flow cytometry) and 10 
healthy subjects and analyzed them by flow cytometry 
for percentage of monocytes, neutrophils and stage II/III 
erythroblasts. As shown in Figure 2A, the monocyte and 
granulocyte counts were similar between NB patients 
Table 1: Main features of the cohorts of NB patients analyzed for gene expression profiling, BM smears, flow 
cytometry and cell blood count (CBC)
NB patients
Gene 
expression
% BM smear % Flow 
cytometry
% CBC %
N 44 70 16 115
Sex
Female 17 38.6 33 47.1 9 56.2 51 44.3
Male 27 61.4 37 52.9 7 43.8 64 55.7
Age
< 18 months 24 54.5 33 47.1 10 62.5 55 47.8
≥ 18 months 20 45.5 37 52.9 6 37.5 60 52.2
Stage
L1/L2 34 77.3 20 28.6 10 62.5 64 55.7
M 10 22.7 37 52.8 6 37.5 38 33.0
Ms 13 18.6 13 11.3
MYCN
Amplified 6 13.6 22 31.4 4 25.0 28 24.4
Single copy 35 79.6 43 61.5 12 75.0 72 62.6
ND 3 6.8 5 7.1 0 15 13.0
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(mean±SD % of total cells: monocytes 3.86±2.82; 
granulocytes 29.38±13.49) and healthy subjects (monocytes 
2.46±0.83; granulocytes 29.4±7.76). Conversely, the 
percentage of stage II (CD45-CD35+CD44hiCD117+) and 
stage III (CD45-CD35+CD44lowCD117+) erythroblasts was 
significantly lower in NB patients (median±SEM % of 
total cells, stage II: 2.82±0.72; stage III: 0.85±0.41) than in 
healthy subjects (stage II: 5.96±1.18;stage III: 3.58±1.05; 
p=0.02 and p=0.002, respectively) (Figure 2B), confirming 
that late erythrocytes’ maturation was indeed altered in NB 
patients.
Peripheral blood (PB) samples from NB patients 
displays several abnormalities in different cell 
populations
To check whether the altered count of BM erythrocyte 
precursors impacted on the mature cell population present 
in the periphery, we collected cell blood counts (CBCs) 
at diagnosis from a cohort of 115 patients with localized 
and metastatic NB (Table 1, CBC) and compared them to 
CBCs from 32 age- and sex-matched healthy children. In 
general, all the red blood cell and leukocyte counts were 
within the lower limit of the normal range. However, 
healthy children had significantly higher amount of 
mature erythrocytes (mean±SD x1012cell/L: 4.85±0.38) 
than children with localized (4.34±0.71; p=0.0003) or 
metastatic (mean±SD:3.72±0.58; p<0.0001) NB (Figure 
3A), confirming the impairment observed in the BM. As 
for the other mature hematopoietic cell populations, patients 
with localized NB had significantly higher proportion 
of neutrophils (median±SEM x109cell/L: 5.7±0.45) than 
healthy children (3.1±0.23; p<0.0001) or patients with 
metastatic NB (3.8±0.32; p=0.0015) (Figure 3B). Similarly, 
patients with localized NB had higher platelet count 
(mean±SD x109cell/L: 395±114.3) than healthy children 
Table 2: Functional annotation chart with adjusted P value < 0.01 obtained by running the list of genes significantly 
down-modulated in BM resident cells from patients with metastatic and localized NB as compared to healthy 
children.
Category Term Number of genes % P value Benjamini 
P value
UP_KEYWORDS Hereditary hemolytic anemia 16 4,2 5,50E-18 9,80E-16
UP_KEYWORDS Blood group antigen 16 4,2 3,00E-18 1,10E-15
BIOCARTA Hemoglobin's Chaperone 10 2,6 1,30E-11 1,60E-09
UP_KEYWORDS Phosphoprotein 217 56,5 1,70E-11 2,00E-09
UP_KEYWORDS Heme biosynthesis 9 2,3 3,40E-11 3,00E-09
UP_KEYWORDS Porphyrin biosynthesis 7 1,8 1,00E-09 7,30E-08
GOTERM_BP_DIRECT heme biosynthetic process 10 2,6 1,40E-10 2,50E-07
UP_KEYWORDS Acetylation 109 28,4 4,80E-09 2,90E-07
GOTERM_CC_DIRECT cytosol 115 29,9 1,60E-09 5,60E-07
GOTERM_BP_DIRECT
protoporphyrinogen IX 
biosynthetic process 7 1,8 5,80E-09 5,10E-06
GOTERM_BP_DIRECT
porphyrin-containing compound 
biosynthetic process 6 1,6 7,20E-08 4,30E-05
UP_KEYWORDS Elliptocytosis 5 1,3 7,50E-06 3,80E-04
KEGG_PATHWAY
Porphyrin and chlorophyll 
metabolism 9 2,3 7,50E-06 1,60E-03
GOTERM_BP_DIRECT response to methylmercury 6 1,6 4,00E-06 1,80E-03
UP_KEYWORDS Oxygen transport 5 1,3 7,10E-05 2,80E-03
UP_KEYWORDS Disease mutation 74 19,3 6,80E-05 3,00E-03
UP_KEYWORDS Cytoplasm 121 31,5 1,10E-04 3,80E-03
UP_KEYWORDS Cell cycle 27 7 1,80E-04 5,80E-03
UP_KEYWORDS Transferase 52 13,5 2,30E-04 6,90E-03
UP_KEYWORDS Iron 17 4,4 3,60E-04 9,90E-03
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Table 3: Results of analysis for disease of hematopoietic lineages associated to genes significantly under-expressed in 
BM resident cells from patients with metastatic and localized NB as compared to healthy children.
OMIM_DISEASE Gene name
Acatalasemia, CAT
Anemia, hypochromic microcytic, with iron overload 2, STEAP3
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, GLRX5
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, SLC25A38
Anemia, sideroblastic, X-linked, Protoporphyria, erythropoietic, X-linked, ALAS2
Bleeding disorder, platelet-type, 17, GFI1B
Blood group GIL, AQP3
Blood group, Colton, Aquaporin-1 deficiency, AQP1
Blood group, Diego, Blood group, Waldner, Blood group, Wright, Ovalocytosis, SA 
type, Renal tubular acidosis, distal, AD, Cryohydrocytosis, Blood group, Swann, 
Blood group, Froese, Malaria, resistance to, Renal tubular acidosis, distal, AR, 
Spherocytosis, type 4,
SLC4A1
Blood group, Dombrock, ART4
Blood group, Kell, KEL
Blood group, Kidd, SLC14A1
Blood group, Landsteiner-Wiener, ICAM4
Blood group, Langereis system, Pseudohyperkalemia, familial, 2, due to red cell leak, 
Microphthalmia, isolated, with coloboma 7, Dyschromatosisuniversalishereditaria 3,
ABCB6
Blood group, OK, BSG
Blood group, Radin, Blood group, Scianna system, ERMAP
Blood group, Rhesus, Rh-null disease, amorph type, RHCE
Blood group--Lutheran inhibitor, Hereditary persistence of fetal hemoglobin, 
Dyserythropoietic anemia, congenital, type IV,
KLF1
Bombay phenotype, FUT1
C4B deficiency, C4B
Coproporphyria, Harderoporphyria, CPOX
D-2-hydroxyglutaric aciduria 2, IDH2
Elliptocytosis-2, Pyropoikilocytosis, Spherocytosis, type 3, SPTA1
Erythrocytosis due to bisphosphoglyceratemutase deficiency, BPGM
Erythrocytosis, familial, 1, EPOR
Filippi syndrome, CKAP2L
Glutaricaciduria, type I, GCDH
Glyoxalase II deficiency, HAGH
Heinz body anemia, Thalassemia, alpha-, Hemoglobin H disease, nondeletional, 
Erythrocytosis, Hypochromic microcytic anemia,
HBA2
Heinz body anemias, alpha-, Thalassemias, alpha-, Hemoglobin H disease, 
nondeletional, Erythremias, alpha-, Methemoglobinemias, alpha-,
HBA1
Hemolytic anemia due to adenylate kinase deficiency, AK1
(Continued )
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OMIM_DISEASE Gene name
Hemolytic anemia due to gamma-glutamylcysteinesynthetase deficiency, Myocardial 
infarction, susceptibility to, GCLC
Hermansky-Pudlak syndrome 6, HPS6
Lead poisoning, susceptibility to, Porphyria, acute hepatic, ALAD
Leukemia, acute pre-B-cell, PBX1
Leukemia, megakaryoblastic, with or without Down syndrome, somatic, 
Thrombocytopenia, X-linked, with or without dyserythropoietic anemia, Anemia, 
X-linked, with/without neutropenia and/or platelet abnormalities, Thrombocytopenia 
with beta-thalassemia, X-linked,
GATA1
Leukemia, T-cell acute lymphocytic, somatic, TAL1
Majeed syndrome, LPIN2
Malaria, resistance to, Blood group, Gerbich, GYPC
Malaria, resistance to, Blood group, MN, GYPA
Malaria, resistance to, Blood group, Ss, GYPB
McLeod syndrome with or without chronic granulomatous disease, XK
Mitochondrial complex I deficiency, NDUFS2
Mitochondrial complex III deficiency, nuclear type 6, CYC1
Myelodysplastic syndrome, Myelogenous leukemia, acute, ACSL6
Overhydrated hereditary stomatocytosis, Anemia, hemolytic, Rh-null, regulator type, 
Rh-mod syndrome,
RHAG
Platelet glycoprotein IV deficiency, Coronary heart disease, susceptibility 
to, 7, Malaria, cerebral, reduced risk of, Malaria, cerebral, susceptibility to, 
Macrothrombocytopenia,
CD36
Porphyria cutanea tarda, Porphyria, hepatoerythropoietic, UROD
Porphyria variegata, PPOX
Porphyria, acute intermittent, Porphyria, acute intermittent, nonerythroid variant, HMBS
Porphyria, congenital erythropoietic, UROS
Protoporphyria, erythropoietic, autosomal recessive, FECH
Pyruvate carboxylase deficiency, PC
Ribose 5-phosphate isomerase deficiency, RPIA
Senior-Loken syndrome 9, TRAF3IP1
Spherocytosis, type 1, ANK1
Spherocytosis, type 2, Anemia, neonatal hemolytic, fatal and near-fatal, 
Elliptocytosis-3,
SPTB
Spherocytosis, type 5, EPB42
Succinic semialdehyde dehydrogenase deficiency, ALDH5A1
Symmetric circumferential skin creases, congenital, 1, Cortical dysplasia, complex, 
with other brain malformations 6,
TUBB
Thalassemia due to Hb Lepore, Thalassemia, delta-, HBD
Uric acid concentration, serum, QTL1, Junior blood group system, ABCG2
Warfarin resistance, Vitamin K-dependent clotting factors, combined deficiency of, 2, VKORC1
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Figure 1: (A) Percentages of myeloid, erythroid and lymphoid cell populations present in BM smears, (B) percentages of pro-
erythroblasts, baso-erythroblasts, polychromatophilic and orthocromic erythroblasts present in BM smears from NB patients 
with stage L (grey dots, N=20) and stages M and Ms (black dots, N=50) and healthy children (open dots, N=11).
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Figure 2: (A) Percentages of monocytes and granulocytes, (B) percentages of stage II and III erythroblasts present in BM 
samples from NB patients (closed dots, N=11 for panel A and N=15 for panel B) and healthy subjects (open dots, N=10).
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Figure 3: Peripheral cell blood counts obtained from patients with stage L (gray dots, N=64), stage M and Ms (black 
dots, N=51) and healthy children (open dots, N=32). (A) erythrocytes, (B) neutrophils, (C) platelets, (D) monocytes and (E) 
lymphocytes.
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(297.8±85.25, p<0.0001) or patients with metastatic NB 
(349.3±135.2) (Figure 3C). In contrast, the monocyte count 
was lower in metastatic patients (median±SEM x109cell/L: 
0.4±0.03) than in localized patients (0.5±0.03, p=0.02) or 
healthy children (0.5±0.04, p=0.03) (Figure 3D).
No difference in lymphocyte count (Figure 
3E) was observed among patients with localized NB 
(median±SEMx109cell/L: 3.2±0.31), metastatic NB 
(2.8±0.19) and healthy children (2.85±0.33).
Monocyte, neutrophil and erythrocyte count at 
diagnosis associated with clinical outcome of NB 
patients
Taken together the above findings showed that at 
diagnosis all NB patients had decreased erythrocyte and 
increased platelet count, as compared to healthy children. 
Differently from children with metastatic NB, those with 
localized NB showed a significant increase in neutrophil 
and a normal monocytes’ count. We thus checked whether 
the number of mature neutrophils, monocytes, erythrocytes 
and platelets associated to outcome. NB patients with 
number of neutrophil, monocyte and erythrocyte counts 
above the cut-off values determined by ROC curves 
displayed a significantly better overall survival (OS) than 
those with counts below the cut-off values (Figure 4A, 4B 
and 4C, p=0.0008, p=0.039 and p=0.0048, respectively). In 
contrast, the number of platelets at diagnosis (Figure 4D) 
did not associate with different OS.
The outcome of patients with metastatic NB 
associated with the number of erythrocytes at 
follow-up
Since prognosis of patients with metastatic NB is 
poor despite multimodal therapies, we asked whether in 
Figure 4: Overall survival curves obtained by stratifying the CBC cohort of NB patients (N=115) with number of (A) 
neutrophils, (B) monocytes, (C) erythrocytes and (D) platelets in PB samples above and below the cut-off value determined 
for each cell population by ROC curves (5.7x109/L for neutrophils, 0.4x109/L for monocytes, 3.3x1012/L for erythrocytes and 400x109/L 
for platelets).
Oncotarget53204www.impactjournals.com/oncotarget
this subset of patients erythrocyte count at end of treatment 
or at follow-up associated with outcome. No association 
with event-free survival (EFS) and OS was found at the 
end of the high-risk therapeutic regimen (Supplementary 
Figure 2A and 2B, respectively), whereas patients with 
erythrocyte countsat follow-up above the cut-off value 
displayed significantly better EFS and OS (Supplementary 
Figure 2C and 2D respectively, p=0.0003).
Thus, we checked which of the erythrocyte-related 
analytical parameters, such as mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH), and mean 
corpuscular hemoglobin content (MCHC), hemoglobin, 
hematocrit and red blood cell distribution width (RDW) 
at end of cure and at follow-up also associated to OS. 
No association between MCV, MCH and MCHC values 
was found (data not shown). In contrast, hemoglobin and 
hematocrit values above the cut-off, and RDW values 
below the cut-off significantly associated to better OS, 
both at the end of cure and at follow-up (Figure 5).
Taken together these analyses suggested that 
maintenance of a low number of dis-homogeneous mature 
erythrocytes in the periphery may indicate persistence of 
impaired erythrocyte maturation in the BM. However, 
none of the growth factors and cytokines involved in 
erythrocytes’ maturation, such as SCF, IL-3, IL-4, TPO 
and EPO (http://www.genome.jp/kegg/pathway.html), 
were under-expressed in BM resident cells from NB 
patients as compared to healthy children (Supplementary 
Table 2), suggesting that other, still unknown, factors may 
have a role.
DISCUSSION
So far, the physical occupancy of the BM space by 
metastatic NB cells has been thought to be the cause of 
impaired BM function observed in children with metastatic 
NB. Here, we showed that the impairment was selective 
and occurred only in the erythrocyte lineage, regardless 
of the presence of metastatic NB cells. Both myeloid- 
and lymphoid-lineages were normally represented in 
the BM, as well as the proportion of pro-erythroblasts, 
baso-erythroblasts and poly-chromatophilic erythroblasts. 
Conversely, ortho-chromic erythroblast count was 
significantly lower in NB patients than in healthy children 
and adults, making it unlikely that flow cytometry results 
on fresh BM aspirates could be ascribed to difference in 
age between NB patients and BM donors.We also excluded 
that the decreased representation of blood group antigens 
expressed by mature erythrocytes could be ascribed to 
skewing in NB susceptibility depending on ABO system, 
as observed in other type of cancers [27–29].
In this study we were unable to identify a 
potential cause for such a specific impairment of late 
stage erythrocyte maturation. From the microarray 
data, no cytokines and/or chemokines implicated in 
the erythrocyte maturation were significantly under-
expressed. The finding of a specific impairment of 
erythrocyte maturation at late stages may relate to a 
deficient heme and porphyrin biosynthesis, as suggested 
by bio-informatics analysis. It is interesting to note that 
heme biosynthesis occurs in the mitochondria, the site of 
energetic metabolism and of apoptotic signals [30]. It is 
well known that oxidative stress is enhanced in NB, and 
indeed our previous microarray data showed an increase 
of SOD mRNA expression, as well as altered expression of 
genes involved in glutathione metabolism [24]. Moreover, 
an ultra-structural study on NB primary tumors recently 
showed consistent auto-phagic vacuoles and abnormality 
of mitochondria structure in all undifferentiated NB cells 
[31]. Therefore, it cannot be excluded that the impaired 
erythrocyte maturation observed in patients with NB 
was a peculiar effect consequent to the disruption of 
mitochondria in this particular lineage, and impairment 
of mitochondria structure and/or function may be a more 
general feature of NB tumors.
Since we confirmed here that BM resident cells of 
patients with NB have similar gene expression profiles 
and low erythrocyte counts, independently of the physical 
presence of neoplastic NB cells in the BM space [24], it is 
conceivable that primary tumor cells produced effects at 
distance. In this view it is tempting to speculate that the 
observed impairment could be mediated by extracellular 
vesicles released by the tumor cells, which transfer 
protein, mRNA, miRNA, DNA and lipids to other cells 
[32]. Therefore, further investigations on the potential role 
of NB-related vesicles are warranted.
Differently from children with metastatic NB, 
however, children with localized NB had significantly 
higher platelet and neutrophil counts than healthy children. 
This finding is in accordance with previous observations 
in smaller cohorts, showing that the proportion of innate 
effectors in this subset of patients was higher than in high-
risk patients [33–36]. It has been suggested that increased 
number of innate effectors were responsible for the 
favorable outcome of patients with localized NB. Here, 
we showed that the number of neutrophils associated 
with better survival; however, it remains to be established 
why children with metastatic disease fail to elicit innate 
response. Interestingly, in our study no difference was 
observed in lymphocyte count in both BM and PB, 
limiting the potential role of this lineage in the natural 
history of NB.
Our study has some limitations: it is a mono-center, 
retrospective analysis, which must be confirmed in a 
prospective cooperative international study. However, the 
number of patients with localized and metastatic NB, 
and of controls, is meaningful. In addition, patients were 
diagnosed throughout a decade at the Italian NB reference 
center, and they were all treated according to international 
protocols, thus excluding effects due to different treatment. 
As stated above, we were unable to identify the possible 
cause(s) of erythropoiesis impairment in NB. The disruption 
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Figure 5: Overall survival plots obtained by stratifying stage M NB patients (N=29) with hemoglobin (panels A and B), 
hematocrit (panels C and D) and RDW values (panels E and F) above and below the cut-off value determined by ROC 
curves at end of cure (11.3 g/dL, 33.7% and 14.4%, panels A, C and E, respectively) or at follow-up (12.1 g/dL, 35.3% and 15.7 %, 
panels B, D, and F, respectively).
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of mitochondria structure and/or function, as well as the 
potential role of NB-specific vesicles, as putative player 
in erythrocyte impairment needs to be further addressed. 
The study was limited to children with NB; it would be 
interesting to check whether in children with soft tissue 
sarcomas, and/or in adult cancers with BM as major site of 
metastasis, the same selective impairment occurs.
In conclusion, our study showed that NB cells 
selectively disrupted the late stage of erythrocytes’ 
maturation, thus decreasing their number in the periphery. 
Since failure to fully restore erythrocyte count associated 
with a worse outcome, this observation may be clinically 
relevant. In addition, future studies may lead to understand 
the mechanism(s) responsible for the impairment and 
eventually to a better cure for children with NB.
MATERIALS AND METHODS
NB patients
Patients included in the study were diagnosed with 
NB at the Gaslini Institute between September 2005 and 
March 2016. Written consent for research use of samples 
and clinical data was obtained by the legal guardians. 
The study was approved by the Gaslini Institute Ethical 
Committee and all analyses were performed according to 
the Helsinki declaration.
Disease staging was made according to INSS till 
2010 [37], and to INRG-SS criteria afterwards [12, 38].
For uniformity, the old INSS stage was converted to the 
INRG-Staging. After diagnosis, patients were treated 
according to the European protocol suited for her/his risk 
category, dependent on age, stage and MYCN status.
Demographic, genetic, clinical and follow-up data 
at 31st December 2016 were retrieved from the Italian NB 
Registry [39]. The main features of the patients included 
in the different analysis are summarized in Table 1. All 
the analyses were made using samples taken at diagnosis.
Controls
As controls in BM smears’ evaluation and gene 
expression profiling, samples were obtained from healthy 
siblings of children admitted at the Gaslini Institute to 
undergo BM transplants.
As controls in flow cytometer study, BM aspirates 
were obtained from healthy BM donors, selected according 
to the Transplant Unit Clinical Protocol of Ematologia 2 at 
the IRCCS San Martino-IST in Genoa, following a written 
informed consent at the time of donation. Samples were 
processed as described [40]. At the end of processing, an 
aliquot was taken to perform quality control tests. The 
remaining part was used in this study.
As controls for cell blood counts (CBC), PB samples 
were obtained from age- and sex-matched healthy children 
admitted to the Gaslini Institute for accidental injuries.
RNA extraction, gene expression profiling and 
gene ontology analysis
Total RNA was extracted from BM aspirates of 
13 healthy children, 20 patients with localized NB, 14 
GD2-negative fraction of BM aspirates [24] from patients 
with localized NB and 10 GD2-negative fraction of BM 
aspirates from patients with metastatic NB. Five-hundred 
ng of total RNA were hybridized to Human GE 4x44K 
v2 Microarray Kit (Agilent Technologies, Santa Clara, 
CA) following the One-color microarray-based gene 
expression analysis protocol. Slides were scanned by 
Agilent G2565BA scanner and images were processed 
by Feature Extraction software v.9.5.3.1.Microarray data 
are MIAME compliant and are accessible through GEO 
(http://www.ncbi.nlm.nih.gov/geo/) accession GSE90689.
The genes significantly under-expressed in NB 
patients were run in the DAVID bioinformatics website 
(https://david.ncifcrf.gov/) [41].
Smears analysis, cell blood count (CBC), 
erythrocyte-related parameters, and blood group 
antigens
Six May-Grunwald Giemsa-stained smears of BM 
aspirates were analyzed under light microscope by two 
independent morphologists (FS and MLB).
CBCs and erythrocyte-related parameters were 
obtained by using an automated cell counting device 
(Advia 2120i, Siemens, Milan, Italy).
ABO blood group and Rh negative/positive 
determinations were made according to certified standard 
procedures.
Flow cytometry analysis
Flow cytometer analysis was performed on whole 
BM samples, using 50 µl of whole blood/tube. Briefly, 
samples were incubated with specific antibodies (20’ 
at 4°C in the dark) and then subjected to erythrocytes 
lysis using BD FACS lysis (BD Biosciences, Milan, 
Italy) by incubating 15’ at RT in the dark. Cells were 
washed with PBS 0.5% BSA, suspended in PBS 0.5% 
BSA and run on Gallios cytometer (Beckman Coulter, 
Cassina dei Pecchi, Italy), acquiring at least 104 events. 
Data were analyzed using Kaluza software (Beckman 
Coulter). The antibodies used were: anti-CD45 PC5 
(Beckman Coulter), anti-CD35 FITC (Immunotools, 
Friesoythe, Germany), anti-CD44 PE (Immunotools), 
anti-CD117 APC (Miltenyi Biotec, Calderara di Reno, 
BO, Italy), anti-CD16 PC7 and anti-CD14 FITC 
(Beckman Coulter), following manufacturer’s protocol. 
PB from 11 NB patients and 10 controls were analyzed 
for monocytes and granulocytes, whereas PB from 15 
NB patients and 10 controls were analyzed for stage II 
and III erythroblasts.
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Statistical analyses
For gene expression profiling, text files were acquired 
and analyzed with Rv3.2.1 software using the limma 
package of Bioconductor [42]. Data were preliminarily 
corrected for background and normalized in order to have 
similar distributions across the set of arrays. Ranking of 
genes by their evidence for differential expression was 
made using the paired moderated t-statistics based on 
empirical Bayes moderation of the standard errors.
For other analyses, normal distribution was tested 
by Kolmogorov-Smirnov. When data distribution was not 
normal, differences in median between: i) patients and 
controls, or ii) different groups of patients, were compared 
by Mann-Whitney test. When data distribution was normal 
comparison was made by the t Student test. Analyses were 
made using the Prism software (GraphPad Software Inc., 
La Jolla, CA).
EFS and OS analyses were performed by Kaplan-
Meier method and compared by log-rank test, after 
determining the cut-off value for each parameter. Cut-off 
values were determined by ROC curves, using MedCalc 
Software (version 17.4, MedCalc, Ostend, Belgium) 
and analysis was performed using method developed by 
DeLong et al. [43]. ROC curves for each parameter are 
represented in Supplementary Figure 3.
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